Guardant Health Beats Q3 Expectations, Raises Full-Year Revenue Guidance on Strong Oncology Growth
Guardant Health reports 39% revenue growth in Q3 2025, narrows losses, and increases full-year guidance to $965-970M driven by oncology expansion and Shield screening test adoption.